Head to Head Survey: Harvard Bioscience (HBIO) versus Cytosorbents (CTSO)

Cytosorbents (NASDAQ: CTSO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Valuation and Earnings

This table compares Cytosorbents and Harvard Bioscience’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytosorbents $15.15 million 14.39 -$8.46 million ($0.32) -23.13
Harvard Bioscience $101.88 million 1.71 -$860,000.00 $0.05 98.00

Harvard Bioscience has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cytosorbents and Harvard Bioscience, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytosorbents 0 0 5 0 3.00
Harvard Bioscience 0 0 2 0 3.00

Cytosorbents presently has a consensus price target of $11.05, suggesting a potential upside of 49.32%. Harvard Bioscience has a consensus price target of $9.00, suggesting a potential upside of 83.67%. Given Harvard Bioscience’s higher probable upside, analysts clearly believe Harvard Bioscience is more favorable than Cytosorbents.

Profitability

This table compares Cytosorbents and Harvard Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytosorbents -52.08% -118.07% -40.15%
Harvard Bioscience -0.85% 2.34% 1.64%

Insider & Institutional Ownership

10.8% of Cytosorbents shares are held by institutional investors. Comparatively, 62.3% of Harvard Bioscience shares are held by institutional investors. 5.6% of Cytosorbents shares are held by insiders. Comparatively, 9.8% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Cytosorbents has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Summary

Harvard Bioscience beats Cytosorbents on 11 of the 13 factors compared between the two stocks.

Cytosorbents Company Profile

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, the company is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. It has collaboration with Aferetica srl to develop PerLife ex-vivo organ perfusion system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.